VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib

Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, discusses a Phase II study exploring the use of parsaclisib, a PI3Kdelta inhibitor in myelofibrosis patients that show suboptimal responses to ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter